Science

Biotech CEO reviews the efficacy of ketamine, MDMA & psychedelic therapy for mental health (podcast episode)

According to The New Yorker, ketamine therapy is going mainstream. 

Evidence from studies using this drug to treat mental health issues has been very promising, as stated in the National Library of Medicine, with results showing a significant improvement in depression, anxiety, and the severity of illness after ketamine treatment. 

In today’s episode of the Brains Byte Back podcast, we will explore how this drug is being used and how it stands to impact the future of treating mental illnesses. 

To do this we spoke with Dr. Tiago Marques, CEO of Pasithea Therapeutics, a biotech company at the forefront of research solutions to the world’s mental health problems.

Listen to this podcast on SpotifyAnchorApple PodcastsBreakerGoogle PodcastsStitcherOvercastListen NotesPodBean, and Radio Public.

In the episode, Marques tells us how Pasithea first started, and shares some insights into day-to-day research at the company.

He also explains how mobile clinics and controlled ketamine infusion work. Alongside, how effective ketamine is for treating PTSD, depression, and other similar issues. 

Additionally, he shares how ketamine therapy has demonstrated a 75% efficacy rate for those suffering from treatment-resistant depression. And a 50% efficacy rate for those suffering from PTSD.

And finally, Marques shares exciting trends in the medical space using psychedelics, and explains what legal implications when working in the psychedelic space in the US right now. 

Sam Brake Guia

Sam is an energetic and passionate writer/presenter, always looking for the next adventure. In August 2016 he donated all of his possessions to charity, quit his job, and left the UK. Since then he has been on the road travelling through North, Central and South America searching for new adventures and amazing stories.

View Comments

Recent Posts

Prezent launches My Workspace to ensure AI-powered presentation software works as tool, not a burden

In an ideal scenario, professionals in 2025 should be able to leverage a personal suite…

1 hour ago

NTT’s simultaneous Kabuki performance shows photonics connectivity is more than a song and dance

In a fusion of tradition and technology, Japanese tech firm NTT unveiled the capabilities of…

1 day ago

UN finalizes neurotech ethics draft, to be adopted at General Conference

The United Nations Educational, Scientific, and Cultural Organization (UNESCO) finalizes its "Recommendation on the Ethics…

6 days ago

Inside the Dead Internet Theory: Profits in a World Run by Bots

The dead internet theory is a conspiracy theory that goes: Most of the content we…

1 week ago

Check out the cool new pet-tech at Leap Venture Studio’s 9th Cohort Demo Day

Pet lovers are increasingly turning into tech lovers as well as the pet care world…

2 weeks ago

Tony Blair wants UK to enable animal gene editing, fund precision-bred livestock

Is genetically editing animals really about preventing pandemics, or is there something deeper to it?…

2 weeks ago